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(liver) and/or different nitric oxide donors/doses, and/or
may reflect inherent problems with the assumption that
the gas chromatography–mass spectrometry assay of
dimethylamine (DMA) formation gives a direct measure
of ADMA breakdown (see below). We did find that nitrate
reduced color formation in our DDAH assay (unpublished)
as also reported by Prescott and Jones;5 however, we did
not add nitrate to the assay in our study.1
We agree that 2,3 dimethoxy-1,4-napthoquinone may
have other actions in addition to generation of superoxide.
It would be interesting to see a comparison between
different oxidizing agents, however, Tsikas and co-workers4
do not assess the impact of 2,3 dimethoxy-1,4-napthoqui-
none (or other superoxide generators) using their gas
chromatography–mass spectrometry assay.
Dr Tsikas and Dr Chobanyan suggest that their DMA
production assay provides a definitive DDAH activity
assay, but lacking is any direct evidence that 1 U of DMA
produced¼ 1 U of ADMA consumed under any experi-
mental conditions. The wide range in reported urinary
DMA:ADMA ratios could reflect alterations in ADMA
synthesis, and/or DMA production through other path-
ways, and/or different handling of DMA and ADMA in
specific nephron segments as well as differences in the
proportion of urinary ADMA excretion vs DDAH meta-
bolism of ADMA. In fact, although a promising tool for
study of ADMA metabolism, DMA production rate, like
citrulline production rate, provides only a surrogate
measure of ADMA breakdown and requires validation
against the ‘gold standard’ of ADMA degradation in every
in vivo and in vitro experimental condition.
Although we disagree with the criticisms of Dr
Chobanyan and Dr Tsikas regarding the quality of our
study, we are in agreement that the question of impact of
oxidative stress on DDAH activity remains to be resolved.
Indeed, we recently reported that whereas vitamin E
supplementation was successful in reducing renal cortical
oxidative stress (as measured by reduced nicotinamide
adenine dinucleotide phosphate oxidase-dependent super-
oxide production), renal DDAH activity and plasma
ADMA level was not altered in a rat model of kidney
disease.6 As Dr Vaziri points out, oxidative stress is
extremely heterogenous, may originate from many loca-
tions and in response to many different stimuli.7 It is
possible, therefore, that not all ‘oxidative stress’ is the same
in terms of impact on ADMA levels.
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Does pioglitazone provide a
better renoprotective effect than
insulin in diabetic patients?
Kidney International (2008) 74, 970–971; doi:10.1038/ki.2008.371
To the Editor: In a recent issue of Kidney International,
Ohtomo et al.1 showed that pioglitazone (PGZ), one of these
currently used thiazolidinediones, could provide better
renoprotection than insulin in an obese, hypertensive, type
2 diabetes mellitus rat model. However, a few questions
should be considered for this animal study. First, many
diabetic patients have insulin as their main treatment for
glycemic control, as the author proved PGZ has better
renoprotection, would combination treatment with insulin
and PGZ be a better regimen for diabetic patients? If the
answer is yes, why didn’t the author add another group
treated by both insulin and PGZ in their study design.
Second, the glycemic control was not better in rats treated
with PGZ than those with insulin. Is it possible that the dose
of PGZ was too low to achieve a better glycemic status?
Third, how could we explain the finding that insulin had a
renoprotective effect in the first 8 weeks but it increased urine
protein later gradually? According to Schena and Gesualdo,2
insulin can reduce oxidative stress with prevention of
accumulation of toxic advanced glycation end products,
which may provide renoprotection in the first 8 weeks.
However, in the later period, insulin may induce production
of matrix proliferation and results in glomerular sclerosis,
thus renal function may decline with increased urine protein
excretion.
Finally, the authors only provided a comparison of
clearance of creatinine in each group at 26 weeks. I would
like to have a look at the change of clearance of creatinine in
each group in a time-course manner. There might be an
initial increase of clearance of creatinine in the first 8 weeks
but with a subsequent decrease of it in insulin treated
diabetic rats. This might provide some evidence for
combination treatment with both insulin and PGZ because
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insulin results in renoprotection by reducing oxidative stress
in an earlier period, whereas PGZ does so by inhibiting
transforming growth factor-b production in a later period.3
The above-mentioned points need to be clarified before the
renoprotective effect of thiazolidinedione can be applied to
clinical practice in a large scale.
1. Ohtomo S, Izuhara Y, Takizawa S et al. Thiazolidinediones provide better
renoprotection than insulin in an obese, hypertensive type II diabetic rat
model. Kidney Int 2007; 72: 1512–1519.
2. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic
nephropathy. J Am Soc Nephrol 2005; 1: S30–S33.
3. Morrisey K, Evans RA, Wakefield L et al. Translational regulation of renal
proximal tubular epithelial cell transforming growth factor-beta1
generation by insulin. Am J Pathol 2001; 159: 1905–1915.
Wen-Sheng Liu1, Chih-Ching Lin1 and Wu-Chang Yang1
1Division of Nephrology, Department of Medicine, Faculty of Medicine,
School of Medicine, Taipei Veterans General Hospital, National Yang Ming
University, Taipei, Taiwan, Republic of China
Correspondence: Chih-Ching Lin, Division of Nephrology, Department of
Medicine, Taipei Veterans General Hospital, Faculty of Medicine, School of
Medicine, National Yang Ming University, No. 201, Sec. 2, Shih-Pai Road,
Taipei 11217, Taiwan, Republic of China. E-mail: lincc2@vghtpe.gov.tw
Response to ‘Does pioglitazone
provide a better renoprotective
effect than insulin in diabetic
patients?’
Kidney International (2008) 74, 971; doi:10.1038/ki.2008.373
Liu et al. are apparently concerned mainly with the
potential benefits of a combination of pioglitazone (PGZ)
and insulin treatment in type II diabetes mellitus. In
contrast, as stated in the introduction of our paper,1 we
evaluated whether, despite similar or even worse glucose
levels, renoprotection achieved by PGZ monotherapy (and
its attendant correction of hyperinsulinemia) differed from
that obtained with insulin alone. We did not include,
therefore, a group treated with both insulin and PGZ. In
parenthesis, in a recent review article, Sarafidis and Bakris2
summarized all human clinical and experimental animal
studies relevant to the renoprotective benefits of thiazoli-
dinediones: only 1 out of 29 studies allowed the use of
insulin in combination with thiazolidinediones.
For similar reasons, creatinine clearance was evaluated
only at the end of the study, as we were not interested in a
PGZ–insulin combined treatment.
We agree with Liu et al. that higher PGZ doses might
have further improved glucose control, but a search for a
maximal effect on glucose was beyond the rationale of our
study.
Liu et al. speculate on the transient effect of insulin on
proteinuria. We are unable to comment their hypothesis as
our study was not designed to assess this issue. We should
point out, however, that, contrary to the statement by Liu
et al., Schena and Gesualdo3 do not consider the effect of
insulin treatment on renal oxidative stress.
Our findings demonstrate only that, in a type II diabetic
rat model, PGZ monotherapy improves renoprotection
above that obtained by insulin alone. We speculate that
this benefit is due to fall in circulating insulin levels,
probably through a reduction of transforming growth
factor-b expression. We wholeheartedly agree with Liu
et al. that extension of our conclusions to human disease
requires further clinical studies. In this context, they will
be interested to learn that, in Japan only, a large clinical
study is already in progress based on the potential clinical
benefit of thiazolidinediones in type II diabetics, that is,
the Japan Diabetes Outcome Intervention Trial (3000
patients are to be enrolled),4 and another clinical study is
in the planning stage based on the clinical benefit of PGZ
in type II diabetics, that is, Pioglitazone Multicenter
Intervention Clinical Trial in Hospital of Tohoku Region
Improving Nephropathy, Oxidative Stress, Kidney Injury,
Urinary Albumin Excretions study (200 patients; S Ito,
personal communication).
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Steroids in acute interstitial
nephritis
Kidney International (2008) 74, 971–972; doi:10.1038/ki.2008.374
To the Editor: The article ‘Early steroid treatment improves
the recovery of renal function in patients with drug-induced
acute interstitial nephritis’ has great significance in clinical
practice but needs to be interpreted with caution.1
In this multicenter retrospective analysis the role of
steroids in patients with biopsy-proven drug-induced acute
interstitial nephritis was evaluated in 61 patients. The authors
found that final serum creatinine values in patients who were
treated with steroids, especially early in the course of disease
were significantly lower than the untreated group. In this
study patients were categorized as mild, moderate, and severe
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